Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Common Equity (2017 - 2025)

Aclaris Therapeutics has reported Common Equity over the past 9 years, most recently at $103.1 million for Q4 2025.

  • Quarterly results put Common Equity at $103.1 million for Q4 2025, down 33.73% from a year ago — trailing twelve months through Dec 2025 was $103.1 million (down 33.73% YoY), and the annual figure for FY2025 was $103.1 million, down 33.73%.
  • Common Equity for Q4 2025 was $103.1 million at Aclaris Therapeutics, down from $120.1 million in the prior quarter.
  • Over the last five years, Common Equity for ACRS hit a ceiling of $235.8 million in Q2 2022 and a floor of $103.1 million in Q4 2025.
  • Median Common Equity over the past 5 years was $156.8 million (2023), compared with a mean of $166.2 million.
  • Biggest five-year swings in Common Equity: skyrocketed 431.4% in 2021 and later plummeted 33.73% in 2025.
  • Aclaris Therapeutics' Common Equity stood at $197.3 million in 2021, then rose by 0.14% to $197.6 million in 2022, then decreased by 20.46% to $157.2 million in 2023, then decreased by 1.03% to $155.6 million in 2024, then crashed by 33.73% to $103.1 million in 2025.
  • The last three reported values for Common Equity were $103.1 million (Q4 2025), $120.1 million (Q3 2025), and $131.7 million (Q2 2025) per Business Quant data.